Screening for Primary Aldosteronism in the Diabetic Population: a cohort study

2022 ◽  
Author(s):  
Suzanne Joy Tan ◽  
Renata Libianto ◽  
Jun Yang ◽  
Jennifer Wong
Keyword(s):  
Cohort Study ◽  
Primary Aldosteronism ◽  
Diabetic Population

Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study

Hypertension ◽  
2021 ◽  
Author(s):  
Gregory L. Hundemer ◽  
Haris Imsirovic ◽  
Anand Vaidya ◽  
Nicholas Yozamp ◽  
Rémi Goupil ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Primary Aldosteronism ◽  
Retrospective Cohort ◽  
Cox Regression ◽  
Time Window ◽  
Population Level ◽  
Population Based ◽  
Clinical Predictors ◽  
Antihypertensive Medications

Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Hypertension plus hypokalemia is a guideline-recommended indication to screen for primary aldosteronism, yet the uptake of this recommendation at the population level remains unknown. We performed a population-based retrospective cohort study of adults ≥18 years old in Ontario, Canada, with hypertension plus hypokalemia (potassium <3.5 mEq/L) from 2009 to 2015 with follow-up through 2017. We measured the proportion of individuals who underwent primary aldosteronism screening via the aldosterone-to-renin ratio based upon hypokalemia frequency and severity along with concurrent antihypertensive medication use. We assessed clinical predictors associated with screening via Cox regression. The cohort included 26 533 adults of which only 422 (1.6%) underwent primary aldosteronism screening. When assessed by number of instances of hypokalemia over a 2-year time window, the proportion of eligible patients who were screened increased only modestly from 1.0% (158/15 983) with one instance to 4.8% (71/1494) with ≥5 instances. Among individuals with severe hypokalemia (potassium <3.0 mEq/L), only 3.9% (58/1422) were screened. Among older adults prescribed ≥4 antihypertensive medications, only 1.0% were screened. Subspecialty care with endocrinology (hazard ratio [HR], 1.52 [95% CI, 1.10–2.09]), nephrology (HR, 1.43 [95% CI, 1.07–1.91]), and cardiology (HR, 1.39 [95% CI, 1.14–1.70]) were associated with an increased likelihood of screening, whereas age (HR, 0.95 [95% CI, 0.94–0.96]) and diabetes (HR, 0.66 [95% CI, 0.50–0.89]) were inversely associated with screening. In conclusion, population-level uptake of guideline recommendations for primary aldosteronism screening is exceedingly low. Increased education and awareness are critical to bridge this gap.

Microalbuminuria as an early predictor of preeclampsia in the pre-gestational diabetic population: A prospective cohort study

2019 ◽  
Vol 15 ◽  
pp. 182-188
Author(s):  
Monica Zen ◽  
Suja Padmanabhan ◽  
Ngai Wah Cheung ◽  
Adrienne Kirby ◽  
Shilpa Jesudason ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Diabetic Population ◽  
Early Predictor

scholarly journals Primary aldosteronism is associated with risk of urinary bladder stones in a nationwide cohort study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mu-Chi Chung ◽  
Cheng-Li Lin ◽  
Ming-Ju Wu ◽  
Cheng-Hsu Chen ◽  
Jeng-Jer Shieh ◽  
...  
Keyword(s):  
Cohort Study ◽  
Primary Aldosteronism ◽  
Risk Model ◽  
Population Based ◽  
Bladder Stones ◽  
Risk Of Death ◽  
Cox Proportional Hazard ◽  
Hazard Ratios ◽  
Taiwan National Health Insurance ◽  
Cox Proportional Hazard Models

AbstractWe analyzed database from the Taiwan National Health Insurance to investigate whether primary aldosteronism (PA) increases the risk of bladder stones. This retrospective nationwide population-based cohort study during the period of 1998–2011 compared patients with and without PA extracted by propensity score matching. Cox proportional hazard models and competing death risk model were used to estimate the hazard ratios (HRs), sub-hazard ratios (SHRs) and corresponding 95% confidence intervals (CIs). There were 3442 patients with PA and 3442 patients without PA. The incidence rate of bladder stones was 5.36 and 3.76 per 1000 person-years for both groups, respectively. In adjusted Cox hazard proportional regression models, the HR of bladder stones was 1.68 (95% CI 1.20–2.34) for patients with PA compared to individuals without PA. Considering the competing risk of death, the SHR of bladder stones still indicates a higher risk for PA than a comparison cohort (SHR, 1.79; 95% CI 1.30–2.44). PA, age, sex, and fracture number were the variables significantly contributing to the formation of bladder stones. In conclusion, PA is significantly associated with risk of bladder stones.

scholarly journals Time-Varying Risk of Atrial Fibrillation in Patient With Medically and Surgically Treated Primary Aldosteronism: A Nationwide Cohort Study

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A301-A301
Author(s):  
Kyoung Jin Kim ◽  
Namki Hong ◽  
Seunghyun Lee ◽  
Yumie Rhee ◽  
Jung Soo Lim
Keyword(s):  
Atrial Fibrillation ◽  
Cohort Study ◽  
Primary Aldosteronism ◽  
Drug Group ◽  
Hazard Ratio ◽  
Adjusted Hazard Ratio ◽  
Time Dependent ◽  
Time Varying ◽  
Fatal Stroke ◽  
Surgery Group

Abstract Evidence of increased cardiovascular risk, especially atrial fibrillation, has been accumulating among patients with primary aldosteronism (PA), but there is still limited information about long-term prognosis related to different treatment strategy. The aim of this study was not only to investigate the incidence of atrial fibrillation, but also to evaluate their time-dependent changes after adrenalectomy (surgery group) or mineralocorticoid receptor antagonists (drug group) for patients with PA compared to those with essential hypertension (EH). From a nationwide cohort in Korea (2003–2017), PA were individually matched for sex, age (±10 years), and index year in a 1:5 ratio with EH. The primary end point was the time-varying risk of new-onset atrial fibrillation (NOAF) among PA according to treatment mode compared to EH. The secondary end points were the risks of major adverse cardiovascular events (composite of non-fatal myocardial infarction, non-fatal stroke, and death from cardiovascular causes), hospitalization for heart failure, and all-cause mortality. Cox proportional-hazards analysis or time-dependent Cox analysis based on the Schoenfeld residuals testing were performed. We enrolled 1,418 PA patients (755 in PA surgery group and 663 in PA drug group), and matched theses with 7,090 EH controls with a median of 5 years. The risk of incident NOAF was statistically higher in patients with PA (both surgery and drug groups) within the three years after diagnosis (adjusted hazard ratio, 3.02; p&lt;0.001), whereas there was no statistically significance after the three years compared to EH (adjusted hazard ratio, 0.50; p=0.053). Patients in the PA drug group had higher risk of non-fatal stroke during the total followed up period (adjusted hazard ratio, 1.53, p=0.031), although the PA surgery group didn’t. In contrast, patients with PA had no statistically significant difference in risks for other secondary cardiovascular outcomes. In conclusion, this propensity cohort study of adults with PA demonstrated the changeable risk of NOAF over time possibly due to the residual effect of inappropriate aldosterone levels. These findings can provide clinically relevant guidance in the monitoring the cardiovascular complications, especially NOAF and non-fatal stroke, even after treatment among patients with PA. Acknowledgements: This study was supported by Collaborative Research Project of Korean Endocrine Society and National Health Insurance Sharing Service (NHIS-2019-4-005). We also thank Minheui Yu and Doori Cho, the members of the SENTINEL (Severance ENdocrinology daTa scIeNcE pLatform) team for technical assistance in searching and summarizing the relevant literature (4-2018-1215).

Sign in / Sign up

Export Citation Format

Share Document